Role of NF-κB and Akt/PI3K in the resistance of pancreatic carcinoma cell lines against gemcitabine-induced cell death

Oncogene

Volumn 22, Issue 21, 2003, Pages 3243-3251

  Arlt, Alexander ^a   Gehrz, Andre ^a   Müerköster, Susanne ^a   Vorndamm, Jens ^b   Kruse, Marie Luise ^a   Fölsch, Ulrich R ^a   Schäfer, Heiner ^a  

^a UNIVERSITY OF KIEL   (Germany)

^b NONE

Author keywords

Chemotherapy; DNA damage; Programmed cell death; Protein kinase; Transcription factor

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; GEMCITABINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN KINASE INHIBITOR; 2-(4-MORPHOLINYL)-8-PHENYL-4H-1-BENZOPYRAN-4-ONE; AKT1 PROTEIN, HUMAN; ANTINEOPLASTIC ANTIMETABOLITE; CHROMONE DERIVATIVE; DEOXYCYTIDINE; DRUG DERIVATIVE; ENZYME INHIBITOR; ETOPOSIDE; MORPHOLINE DERIVATIVE; ONCOPROTEIN; PROTEIN SERINE THREONINE KINASE;

APOPTOSIS; ARTICLE; CARCINOGENESIS; CELL DEATH; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG MECHANISM; DRUG RESISTANCE; ENZYME ACTIVITY; ENZYME INDUCTION; HUMAN; HUMAN CELL; IMMUNOMODULATION; PANCREAS CARCINOMA; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TIME SERIES ANALYSIS; TUMOR CELL LINE; ADENOCARCINOMA; CELL CULTURE; DOSE RESPONSE; DRUG ANTAGONISM; ENZYMOLOGY; METABOLISM; PANCREAS TUMOR; PHYSIOLOGY;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ADENOCARCINOMA; ANTIMETABOLITES, ANTINEOPLASTIC; APOPTOSIS; CHROMONES; DEOXYCYTIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; ENZYME INHIBITORS; ETOPOSIDE; HUMANS; MORPHOLINES; NF-KAPPA B; PANCREATIC NEOPLASMS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; TUMOR CELLS, CULTURED;

EID: 0038621384     PISSN: 09509232     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.onc.1206390     Document Type: Article

References (42)

1. Alessi DR, James SR, Downes CP, Holmes AB, Gaffney PR, Reese CB and Cohen P. (1997). Curr. Biol., 7, 261-269.
2. Arlt A and Schäfer, H. (2002). Int. J. Clin Pharm. Ther., 40, 336-347.
3. Arlt A, Vorndamm J, Breitenbroich M, Fölsch UR, Kalthoff H, Schmidt WE and Schäfer, H. (2001). Oncogene, 20, 859-868.
4. Arlt A, Vorndamm J, Muerköster S, Yu H, Schmidt WE, Fölsch UR and Schäfer H. (2002). Cancer Res., 62, 910-916.
5. Bian X, McAllister-Lucas LM, Shao F, Schumacher KR, Feng Z, Porter AG, Castle VP and Opipari Jr AW. (2001). J. Biol. Chem., 276, 48921-48929.
6. Bian X, Opipari Jr AW, Ratanaproeksa AB, Boitano AE, Lucas PC and Castle VP. (2002). J. Biol. Chem., 26, 26.
7. Brognard J, Clark AS, Ni Y and Dennis PA. (2001). Cancer Res., 61, 3986-3997.
8. Brunn GJ, Williams J, Sabers C, Wiederrecht G, Lawrence Jr JC and Abraham RT. (1996). EMBO J., 15, 5256-5267.
9. Burris III HA, Moore M J, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD and Von Hoff DD. (1997). J. Clin. Oncol., 15, 2403-2413.
10. Crnogorac-Jurcevic T, Efthimiou E, Nielsen T, Loader J, Terris B, Stamp G, Baron A, Scarpa A and Lemoine NR. (2002). Oncogene, 21, 4587-4594.
11. Dong QG, Sclabas GM, Fujioka S, Schmidt C, Peng B, Wu T, Tsao MS, Evans DB, Abbruzzese JL, McDonnell TJ and Chiao PJ. (2002). Oncogene, 21, 6510-6519.
12. Dumontet C, Fabianowska-Majewska K, Mantincic D, Callet Bauchu E, Tigaud I, Gandhi V, Lepoivre M, Peters GJ, Rolland MO, Wyczechowska D, Fang X, Gazzo S, Voorn DA, Vanier-Viornery A and MacKey J. (1999). Br. J. Haematol., 106, 78-85.
13. Galmarini CM, Clarke ML, Falette N, Puisieux A, Mackey JR and Dumontet C. (2002). Int. J. Cancer, 97, 439-445.
14. Ghosh S, May MJ and Kopp EB. (1998). Annu. Rev. Immunol., 16, 225-260.
15. Goan YG, Zhou B, Hu E, Mi S and Yen Y. (1999). Cancer Res., 59, 4204-4207.
16. Goldstein LJ, Galski H, Fojo A, Willingham M, Lai SL, Gazdar A, Pirker R, Green A, Crist W and Brodeur GM. (1989). J. Natl. Cancer Inst., 81, 116-124.
17. Greenlee RT, Hill-Harmon MB, Murray T and Thun M. (2001). CA Cancer J. Clin., 51, 15-36.
18. Grisham MB, Palombella VJ, Elliott PJ, Conner EM, Brand S, Wong HL, Pien C, Mazzola LM, Destree A, Parent L and Adams J. (1999). Methods Enzymol., 300, 345-363.
19. Hui YF and Reitz J. (1997). Am. J. Health Syst. Pharm., 54, 162-70; quiz 197-198.
20. Kalthoff H, Schmiegel W, Roeder C, Kasche D, Schmidt A, Lauer G, Thiele HG, Honold G, Pantel K, Riethmuller G, Scherer E, Maurer J, Maacke H and Deppert W. (1993). Oncogene, 8, 289-298.
21. Kaltschmidt B, Kaltschmidt C, Hofmann TG, Hehner SP, Droge W and Schmitz ML. (2000). Eur. J. Biochem., 267, 3828-3835.
22. Karin M, Cao Y, Greten FR and Li ZW. (2002). Nat. Rev. Cancer, 2, 301-310.
23. Madrid LV, Wang CY, Guttridge DC, Schottelius AJ, Baldwin Jr AS and Mayo MW. (2000). Mol. Cell. Biol., 20, 1626-1638.
24. Moore PS, Sipos B, Orlandini S, Sorio C, Real FX, Lemoine NR, Gress T, Bassi C, Kloppel G, Kalthoff H, Ungefroren H, Lohr M and Scarpa A. (2001). Virchows Arch., 439, 798-802.
25. Ng SS, Tsao MS, Nicklee T and Hedley DW. (2001). Clin. Cancer Res., 7, 3269-3275.
26. Ng SSW, Tsao MS, Chow S and Hedley DW. (2000). Cancer Res., 60, 5451-5455.
27. Oya M, Ohtsubo M, Takayanagi A, Tachibana M, Shimizu N and Murai M. (2001). Oncogene, 20, 3888-3896.
28. Rayet B and Gelinas C. (1999). Oncogene, 18, 6938-6947.
29. Reddy SA, Huang JH and Liao WS. (2000). J. Immunol., 164, 1355-1363.
30. Rosenberg L. (1997). Int. J. Pancreatol., 22, 81-93.
31. Rosewicz S and Wiedenmann B. (1997). Lancet, 349, 485-489.
32. Ruiz van Haperen VW, Veerman G, Eriksson S, Stegmann AP and Peters GJ. (1995). Semin. Oncol., 22, 35-41
33. Schäfer H, Diebel J, Arlt A, Trauzold A and Schmidt WE. (1998). FEBS Lett., 436, 139-143.
34. Sekulic A, Hudson CC, Homme JL, Yin P, Otterness DM, Karnitz LM and Abraham RT. (2000). Cancer Res., 60, 3504-3513.
35. Trauzold A, Wermann H, Arlt A, Schutze S, Schäfer H, Oestern S, Roder C, Ungefroren H, Lampe E, Heinrich M, Walczak H and Kalthoff H. (2001). Oncogene, 20, 4258-4269.
36. Vanhaesebroeck B, Leevers SJ, Ahmadi K, Timms J, Katso R, Driscoll PC, Woscholski R, Parker PJ and Waterfield MD. (2001). Annu. Rev. Biochem., 70, 535-602.
37. Vivanco I and Sawyers CL. (2002). Nat. Rev. Cancer, 2, 489-501.
38. Wang CY, Mayo MW and Baldwin Jr AS. (1996). Science, 274, 784-787.
39. Wang W, Abbruzzese JL, Evans DB and Chiao PJ. (1999a). Oncogene, 18, 4554-4563.
40. Wang W, Abbruzzese JL, Evans DB, Larry L, Cleary KR and Chiao PJ. (1999b). Clin. Cancer Res., 5, 119-127.
41. Warshaw AL, Gu ZY, Wittenberg J and Waltman AC. (1990). Arch. Surg., 125, 230-233.
42. Weber CK, Liptay S, Wirth T, Adler G and Schmid RM. (2000). Gastroenterology, 119, 1209-1218.